The Readout Loud
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson's exit from his decades-long tenure at the University of Pennsylvania. We also discuss the latest news in the life sciences, including the surprising collapse of a gene editing company, Eli Lilly's pitch to consumers, and more.